Atara Biotherapeutics: Nguyen proposes $49.2K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atara Biotherapeutics, Inc. (ATRA) is identified as the issuer in director and officer AnhCo Nguyen’s Form 144 notice covering 5,981 common shares, with an approximate sale date of November 16, 2026 and an aggregate market value of $49,223.63. Nguyen acquired 13,887 common shares from the issuer on November 15, 2026, through settlement of vested RSUs under an S-8 Registration Plan, as equity compensation for services rendered. The remarks describe shares sold automatically to satisfy tax withholding obligations under a sale-to-cover provision in the award agreement.
Key Figures
Key Terms
RSUs technical
S-8 Registration Plan regulatory
sale-to-cover provision financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.